Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
David D. Waters(San Francisco General Hospital), Jacques Lespérance(Montreal Heart Institute), B P Kimball(Hartford Hospital), M. Le May(Hartford Hospital), Lyall Higginson(University of Ottawa), Peter Gladstone(Hartford Hospital), Stephen J. Boccuzzi(Hartford Hospital)
Cited by 505
Related Papers
Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women
|JAMA|2002|576
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
|New England Journal of Medicine|2006|397
High-Dose Epinephrine in Adult Cardiac Arrest
|New England Journal of Medicine|1992|377
Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial
|The Lancet|2001|346
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
|The Lancet Respiratory Medicine|2021|271